Clinical efficiency of Doxorubicin and Cisplatin in treatment of transmissible venereal tumor of bitches

Basit Öğe Kaydı
dc.contributor.authorCizmeci, S. U.
dc.contributor.authorKose, A. M.
dc.contributor.authorAydin, I.
dc.contributor.authorDinc, D. A.
dc.contributor.authorMaden, M.
dc.contributor.authorKose, S. I.
dc.date.accessioned2020-03-26T18:24:19Z
dc.date.available2020-03-26T18:24:19Z
dc.date.issued2012
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractThe aim of this study was to evaluate the clinical efficiency of doxorubicin and cisplatin, which are used successfully in treatments of genital organ tumors in humans and Transmissible Venereal Tumor (TVT) in bitches. Bitches with TVT (n=17) were included in the study and they were from different breeds, age groups and body weight. Doxorubicin (DOX, 30 mg/m(2), n=9) and cisplatin (CIS, 70 mg/m(2), n=8) were administered to bitches for TVT treatment. Treatment protocol was repeated for 5 times with intervals of 21 days. Hematology, blood gases and serum biochemistry analyses were performed on blood samples collected before and 24 hours after each chemotherapy. Tumor was completely regressed in the animals in DOX group following fifth treatment. Six bitches died in CIS group during treatment. There were no signs of tumor regression in the remaining 2 bitches after third treatment in CIS group. There were leucocytosis and normocytic-hypochromic anemia in all the dogs involved in the therapy. There were significant increases (P<0.05) in blood urea nitrogen (BUN), aspartate aminotransferase (AST) and triglyceride (TRI) concentrations of CIS group and BUN, AST and creatinine phosphokinase (CPK) concentrations of doxorubicin group. It was concluded that cisplatin is ineffective while doxorubicin is effective and can be used safely in treatment of TVT in bitches.en_US
dc.identifier.endpage521en_US
dc.identifier.issn0035-1555en_US
dc.identifier.issn2258-0646en_US
dc.identifier.issue11en_US
dc.identifier.startpage516en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/27827
dc.identifier.volume163en_US
dc.identifier.wosWOS:000312058100004en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherECOLE NATIONALE VETERINAIRE TOULOUSEen_US
dc.relation.ispartofREVUE DE MEDECINE VETERINAIREen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectTransmissible venereal tumoren_US
dc.subjectbitchesen_US
dc.subjectDoxorubicinen_US
dc.subjectCisplatinen_US
dc.titleClinical efficiency of Doxorubicin and Cisplatin in treatment of transmissible venereal tumor of bitchesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu